The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable ...

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When ...

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA) ...

New Phase III data for AstraZeneca's gout drug lesinurad have backed its efficacy ... to placebo on top of background therapy with generic allopurinol in patients who could not achieve effective ...

Dr Hilary Jones has said that the prevalence of gout is set to increase up to 70 per cent in the coming years - and ...

Dr Hilary Jones, resident GP at ITV's Good Morning Britain, said he had discoloured nails, joint pain that would worsen at ...

Pending FDA feedback, the Company will also seek FDA orphan drug designation (“ODD”) and NDA marketing approval for the XRx-026 program. Previously, oxypurinol was granted ODD for allopurinol ...

The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLOTM 1 having advanced ...

About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) ...